Effects of the concomitant administration of tamsulosin (0.8 mg/day) on the pharmacokinetic and safety profile of theophylline (5 mg/kg): A placebo-controlled evaluation

Journal of International Medical Research

Volumn 30, Issue 1, 2002, Pages 34-43

  Miyazawa, Y ^a,d   Starkey, L P ^b   Forrest, A ^c   Schentag, J J ^c   Kamimura, H ^d   Swarz, H ^a   Ito, Y ^a  

^a Yamanouchi USA   (United States)

^b VRG International   (United States)

^c MILLARD FILLMORE HOSPITAL   (United States)

^d ASTELLAS PHARMA INC   (Japan)

Author keywords

Pharmacokinetic interaction; Safety; Tamsulosin; Theophylline

Indexed keywords

ALLOPURINOL; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CIPROFLOXACIN; CLARITHROMYCIN; DILTIAZEM; DISULFIRAM; ENOXACIN; ERYTHROMYCIN; FUROSEMIDE; METHYLXANTHINE; NIFEDIPINE; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; PLACEBO; PROPRANOLOL; RECOMBINANT ALPHA INTERFERON; ROXITHROMYCIN; TAMSULOSIN; THEOPHYLLINE; TROLEANDOMYCIN; VERAPAMIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CHRONIC LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG EFFECT; DRUG INFUSION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART PALPITATION; HUMAN; INTRACTABLE EPILEPSY; MALE; NORMAL HUMAN; ORTHOSTATIC HYPOTENSION; OTALGIA; PROSTATE HYPERTROPHY; SINGLE BLIND PROCEDURE; TABLET FORMULATION; VOMITING;

EID: 0036277266     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000203000106     Document Type: Article

References (26)

1. Identification, quantification and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate
2. The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle
3. Alpha 1-adrenoceptor subtypes in the human prostate
4. 1A-Adrenergic receptors in the isolated human prostate
5. 1C-subtype
6. A randomized, placebo-controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH)
7. 1-adrenoceptor antagonists in benign prostatic hyperplasia: Rationale and clinical experience
8. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH)
9. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH)
10. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia
11. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: Placebo-controlled, double-blind extension of phase III trial
12. A second phase III multi-center placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia
13. 1-blocker, YM617, in the treatment of benign prostatic hypertrophy
14. Prescribing Information
15. Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia
16. Therapeutic consequences of drug interactions with theophylline pharmacokinetics
17. Pharmacokinetic interactions between theophylline and other medication
18. Metabolism of theophylline by cDNA-expressed human cytochromes P-450
19. 1-adrenoceptor blocker tamsulosin in human liver microsomes
20. Validity of creatinine clearance estimates in the assessment of renal function
21. SHAM, a method for biexponential curve resolution using initial slope, height, area, and moment of experimental decay type curve
22. Noncompartmental vs compartmental analysis. Some bases for choice
23. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability
24. Comparison of ultrafiltration devices for assessing theophylline protein binding